← All trials
NCT04851964
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2021
- Primary completion
- Feb 2, 2024
- Completion date
- Apr 26, 2024
- First posted
- Apr 21, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- AmgenCollaborator
- University of DundeeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.